The 3xTG-AD mouse model is a triple transgenic mouse model of Alzheimer's disease that expresses three mutant genes associated with familial AD: APP Swedish, MAPT P301L, and PSEN1 M146V. This model, developed by Oddo et al. in 2003, is unique in that it develops both amyloid-beta (Aβ) plaques and neurofibrillary tangles (NFTs), making it a valuable tool for studying AD pathogenesis and the interaction between the two hallmark pathologies[@oddo2003].
The 3xTG-AD model has become one of the most widely used animal models for AD research due to its ability to reproduce both major pathological hallmarks of the disease in a temporal pattern that roughly mirrors human disease progression. Researchers have utilized this model to investigate disease mechanisms, test therapeutic interventions, and explore the relationship between amyloid and tau pathologies[@querfurth2010].
The 3xTG-AD model contains three human transgenes driven by neuron-specific promoters[@oddo2003a].
| Gene | Mutation | Promoter | Effect |
|---|---|---|---|
| APP | Swedish (KM670/671NL) | Thy1.2 | Increased Aβ production |
| MAPT (Tau) | P301L | Thy1.2 | Tau aggregation |
| PSEN1 | M146V | Endogenous (knock-in) | Altered γ-secretase |
The Swedish double mutation (K670N/M671L) in the APP gene was originally identified in a Swedish family with early-onset familial AD. This mutation is located at the β-secretase cleavage site and increases amyloid-beta production by 3-4 fold, particularly increasing the more aggregation-prone Aβ₁₋₄₂ species. The Thy1.2 promoter drives neuron-specific expression, leading to accumulation of Aβ primarily in the brain rather than peripheral tissues[@oddo2003].
The P301L tau mutation in MAPT is associated with frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17). This mutation promotes hyperphosphorylation and aggregation of tau into neurofibrillary tangles by reducing microtubule binding affinity. In the 3xTG-AD model, tau pathology develops progressively with age, first appearing in the hippocampus and then spreading to cortical regions[@oddo2004].
The M146V presenilin-1 mutation in PSEN1 is a familial AD mutation that enhances γ-secretase activity, leading to increased Aβ₁₋₄₂ production. The mutation is knocked into the endogenous mouse Psen1 locus, ensuring physiologically appropriate expression levels. This knock-in approach prevents the overexpression artifacts that can occur with transgenic constructs[@laferla2012].
The amyloid pathology in 3xTG-AD mice follows a defined temporal progression. At 6 months, diffuse Aβ deposits appear in the subiculum and cortex. By 12 months, plaque density increases significantly throughout the hippocampus and cortex. The plaques are primarily composed of Aβ₁₋₄₂ with some Aβ₁₋₄₀, matching the human AD pattern where Aβ₄₂ initiates aggregation[@oddo2004].
Tau pathology develops after Aβ pathology, consistent with the amyloid cascade hypothesis. The P301L mutation promotes aggregation, but true neurofibrillary tangles are limited by species differences in tau sequence. The model shows phosphorylated tau at multiple epitopes, including AT8 (Ser202/Thr205), AT180 (Thr231), and PHF-1 (Ser396/404)[@hansson2019].
Synaptic dysfunction is one of the earliest measurable deficits in the 3xTG-AD model. Electrophysiological studies reveal impaired LTP in the hippocampal CA1 region as early as 3-4 months, before the appearance of Aβ plaques or tau tangles. This early synaptic impairment is thought to result from soluble Aβ oligomers that accumulate intracellularly and disrupt synaptic function[@billings2005][@singh2015].
Cognitive deficits in 3xTG-AD mice develop in an age-dependent manner. At 6 months, mice show impaired performance in the Morris water maze, particularly in the reversal learning phase. Y-maze testing reveals working memory deficits by 9 months. Anxiety-like behavior is often reduced, possibly reflecting limbic system involvement[@gimenez2009].
The 3xTG-AD model exhibits robust neuroinflammation, with microglial activation accompanying Aβ and tau pathology. Activated microglia cluster around Aβ plaques, adopting a disease-associated microglia (DAM) phenotype. These microglia attempt to clear Aβ through phagocytosis but may become dysfunctional, contributing to chronic inflammation[@le2014].
Microglial activation can be detected using Iba1 immunohistochemistry, with increased staining density around plaques and in regions of tau pathology. The inflammatory response includes production of cytokines such as IL-1β, TNF-α, and IL-6, which may contribute to synaptic dysfunction and disease progression.
Reactive astrocytes are also prominent in the 3xTG-AD model. GFAP-positive astrocytes show hypertrophy and increased proliferation in response to neuropathology. Astrocytic responses include both potentially beneficial functions (Aβ sequestration, neurotrophic support) and detrimental effects (excitotoxicity, inflammatory mediator release)[@rodriguez2013].
The 3xTG-AD model demonstrates significant mitochondrial dysfunction. Proteomic studies have identified altered expression of mitochondrial proteins involved in energy metabolism, oxidative phosphorylation, and antioxidant defenses. These changes precede visible pathology and may contribute to neuronal vulnerability[@perez2005][@bai2020].
Complex I and IV activity is reduced in aged 3xTG-AD mice, leading to impaired ATP production. This energy deficit is particularly pronounced in hippocampus and cortex, the regions most affected by Aβ and tau pathology.
In vivo imaging studies have demonstrated cerebral glucose hypometabolism in the 3xTG-AD model, similar to patterns observed in human AD patients. PET imaging using fluorodeoxyglucose (FDG) shows reduced glucose uptake in the hippocampus and cortex that correlates with cognitive deficits[@yang2018].
Autophagy is impaired in the 3xTG-AD model, with accumulation of autophagic vacuoles in neurons. This impairment affects the clearance of both Aβ and tau, contributing to protein aggregation. The mTOR pathway shows dysregulation, and restore of autophagy through pharmacological approaches has shown promise in reducing pathology[@zhang2019].
Lysosomal cathepsin activity is altered in the 3xTG-AD model, with reduced activity of several hydrolases. This lysosomal dysfunction prevents proper degradation of protein aggregates and contributes to the accumulation of Aβ and tau in intracellular compartments.
The 3xTG-AD model shows impaired adult hippocampal neurogenesis in the subgranular zone of the dentate gyrus. Reduced proliferation of neural progenitor cells and decreased survival of new neurons contribute to cognitive deficits. This impairment may be mediated by Aβ toxicity and inflammatory changes in the neurogenic niche[@mu2020].
| Feature | 3xTG-AD | APP/PS1 |
|---|---|---|
| Amyloid plaques | Yes | Yes |
| Neurofibrillary tangles | Yes | No |
| Tau pathology | Yes | No |
| Onset (plaques) | 6 months | 6-9 months |
| Dual pathology | Yes | No |
| Feature | 3xTG-AD | Tg2576 |
|---|---|---|
| Mutation | APP Swedish + Tau + PS1 | APP Swedish only |
| Plaques | Yes | Yes |
| Tangles | Yes | No |
| Cognitive deficits | More severe | Moderate |
| Age of onset | 6 months | 9-12 months |
| Feature | 3xTG-AD | 5XFAD |
|---|---|---|
| APP mutations | 1 (Swedish) | 3 (Swedish, Florida, London) |
| PSEN1 mutations | 1 (M146V) | 1 (L383) |
| Tau mutation | Yes (P301L) | No |
| Plaque onset | 6 months | 2 months |
| Tangle formation | Yes | Minimal |
The 3xTG-AD model is widely used to test[@laferla2012]:
The dual pathology of the 3xTG-AD model makes it particularly valuable for testing therapies that target both Aβ and tau, which is thought to be necessary for meaningful disease modification in human AD.
Studies using the 3xTG-AD model have demonstrated that Aβ pathology can accelerate tau propagation, supporting the hypothesis that Aβ drives downstream tau pathology[@pooler2012].
The 3xTG-AD model has been instrumental in validating CSF and imaging biomarkers that translate between preclinical studies and human clinical trials.
The model has been used to test numerous therapeutic approaches:
The 3xTG-AD colony requires careful genetic monitoring. Regular genotyping is essential to maintain the triple transgenic status. The model can be maintained as homozygous or heterozygous breeding, with homozygous breeders producing more consistent phenotypes but requiring more intensive colony management.
Standardized behavioral testing protocols have been developed for the 3xTG-AD model. The recommended battery includes:
Recommended immunohistochemistry for pathological assessment: